FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Rising Pharma Holding buPROPion Hydrochloride Extended-Release Recall

buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx…

Rising Pharma Holding, Inc. · East Brunswick, NJ

Risk level
Class II
Reported by FDA
Jan 17, 2024
Recall ID
D-0222-2024
Check your lot numberHow we source this data

Summary

Rising Pharma Holding recalled buPROPion Hydrochloride Extended-Release starting Dec 29, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0222-2024 on Jan 17, 2024. Reason: Presence of Foreign Tablets/Capsules. Status: Ongoing.

Why it was recalled

Presence of Foreign Tablets/Capsules

Product description

buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, INDIA, NDC 16571-862-03

Lot numbers, UPCs & expiration codes

Lot #: BPA123098A, Exp. Date 06/2025

Where it was sold

Nationwide within the United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0222-2024
Classification
Class II
Status
Ongoing
Recall initiated
Dec 29, 2023
FDA report date
Jan 17, 2024
Quantity
47,976 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Rising Pharma Holding, Inc.

Original FDA data

Every field from FDA enforcement report D-0222-2024, exactly as published.

Show all FDA fields
City
East Brunswick
State
NJ
Status
Ongoing
Country
United States
Event ID
93706
Address
2 Tower Center Blvd Ste 1401
Code information
Lot #: BPA123098A, Exp. Date 06/2025
Postal code
08816-1149
Report date
Jan 17, 2024
Product type
Drugs
Recall number
D-0222-2024
Classification
Class II
Recalling firm
Rising Pharma Holding, Inc.
Product quantity
47,976 bottles
Reason for recall
Presence of Foreign Tablets/Capsules
Voluntary / mandated
Voluntary: Firm initiated
Product description
buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, INDIA, NDC 16571-862-03
Distribution pattern
Nationwide within the United States
Recall initiation date
Dec 29, 2023
Initial firm notification
Letter
Center classification date
Jan 11, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0222-2024, published Jan 17, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls